PALO ALTO, Calif., Jan. 8, 2018 /PRNewswire/ -- Varian (NYSE: VAR)
today announced its Halcyon™ system has received Taiwan
FDA approval, which allows the company to market this new cancer
treatment system in Taiwan. This approval further expands the
global availability of Halcyon and high-quality, cost-effective
cancer treatments.
As an advanced cancer treatment system with a human-centered and
user-friendly design, Halcyon is engineered to revolutionize
clinical workflow, accelerate installation timeframes, expedite
commissioning, simplify training, and automate treatment. It
simplifies and enhances virtually every aspect of image-guided
volumetric intensity modulated radiotherapy (IMRT). It is well
suited to handle the majority of cancer patients, offering advanced
treatments for lung, esophagus, brain, head & neck, and many
other forms of cancer.
"We are very proud to further expand Halcyon's global
availability, and with Taiwan FDA approval, clinicians in
Taiwan now can take advantage of
the unique capabilities of this system," said Kevin O'Reilly, president of Asia Pacific for Varian. "We look
forward to further growing Halcyon's availability as we partner
with our customers in the fight against cancer."
Halcyon has already received FDA 510(k) clearance in the US, CE
mark in Europe, Shonin approval in
Japan and ANVISA registration in
Brazil since its launch in
May 2017. First treatments have shown
Halcyon's human-centered and user-friendly design can enhance
patient comfort and increase the treatment efficiency. With the
streamlined workflow, Halcyon only requires nine steps from the
start to the end of treatment compared to up to more than 30 steps
with older technologies.
For more information on Halcyon visit
www.varian.com/halcyon.
About Varian
Varian focuses energy on saving lives
and is the world's leading manufacturer of medical devices and
software for treating and managing cancer. Headquartered in
Palo Alto, California, Varian
employs approximately 6,500 people around the world. For more
information, visit http://www.varian.com and follow @VarianMedSys
on Twitter.
Press Contact
Mark Plungy
Director, Public Relations
+1 (650) 424-5630
mark.plungy@varian.com
Investor Relations Contact
J. Michael Bruff
Vice President, Investor Relations
+1 (650) 424-5163
mike.bruff@varian.com
View original
content:http://www.prnewswire.com/news-releases/varian-halcyon-treatment-system-receives-taiwan-fda-approval-300578338.html
SOURCE Varian